<DOC>
	<DOC>NCT02821624</DOC>
	<brief_summary>This first-in-human (FIH) study will provide the first safety and pharmacokinetic (PK) data for G1T38 in humans and will allow further development of G1T38 in patients with cancer.</brief_summary>
	<brief_title>First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male and female volunteers, 4065 years of age; no clinically significant findings reported following detailed physical examination, medical history, vital signs, clinical laboratory tests, and ECGs as deemed by the PI Body mass index (BMI) in the range of 18 to 32 kg/m2 (inclusive) at screening, and weighing at least 50 kg Nonusers of nicotinecontaining products for at least the previous 3 months prior to dosing or nonsmokers Agreement to use birth control during the study and 3 months post last visit. Able to comply with all protocol requirements and procedures Clinically significant abnormalities found during physical examinations, medical history review, ECGs (QTcF interval &gt; 450 milliseconds for males and &gt;470 milliseconds for females), vital signs, and laboratory tests (including positive HIV, hepatitis B and C) Participated in in a previous clinical study with an investigational product in the last 60 days History of any serious allergic reaction to any medication Any blood or plasma donation or other loss of blood at a volume exceeding 500 mL within 3 months before dosing History of drug or alcohol abuse in the last 2 years Pregnant or lactating women Any other issues which, in the opinion of the PI, will make the subject ineligible for study participation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>